{"id":"NCT01780935","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration","officialTitle":"A 24-month, Phase IIIb, Randomized, Double-masked, Multicenter Study Assessing the Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-03","primaryCompletion":"2015-07-09","completion":"2015-07-09","firstPosted":"2013-01-31","resultsPosted":"2017-01-02","lastUpdate":"2017-08-14"},"enrollment":671,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":[]}],"arms":[{"label":"RBZ 0.5 mg: VA only (Group I)","type":"EXPERIMENTAL"},{"label":"RBZ 0.5 mg: VA and/or OCT (Group II)","type":"EXPERIMENTAL"}],"summary":"This study will evaluate and compare two individualized ranibizumab treatment regimens in patients with neovascular (wet) AMD aiming to achieve and to maintain a maximum visual function benefit, while aiming to avoid unnecessary intravitreal injections.\n\nThe results will be used to generate further recommendations on functional and anatomical monitoring of the disease and timing of treatment administration for patients with neovascular AMD. In this context, the study will investigate the utility of optical coherence tomography (OCT) to aid retreatment decisions with ranibizumab.","primaryOutcome":{"measure":"Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12","timeFrame":"up to Month 12","effectByArm":[{"arm":"RBZ 0.5 mg: VA Only (Group I)","deltaMin":0.1,"sd":6.79},{"arm":"RBZ 0.5 mg: VA and/or OCT (Group II)","deltaMin":1,"sd":7.25}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":92,"countries":["Argentina","Austria","Canada","Colombia","Czechia","Finland","France","Germany","Greece","Guatemala","Hungary","Ireland","Italy","Lithuania","Mexico","Netherlands","Panama","Portugal","Slovakia","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["31918685"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":334},"commonTop":["Nasopharyngitis","Intraocular pressure increased (Study eye)","Hypertension","Influenza","Conjunctival haemorrhage (Study eye)"]}}